Sarepta Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRPT research report →
About the company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations.
- CEO
- Douglas S. Ingram
- IPO
- 1997
- Employees
- 1,372
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $2.04B
- P/E
- 31.10
- P/S
- 0.93
- P/B
- 1.34
- EV/EBITDA
- 20.87
- Div Yield
- 0.00%
- Gross Margin
- 62.39%
- Op Margin
- -1.88%
- Net Margin
- 2.98%
- ROE
- 4.89%
- ROIC
- -1.53%
- Revenue
- $2.20B · 15.58%
- Net Income
- $-713,410,000 · -403.27%
- EPS
- $-7.13 · -388.66%
- Op Income
- $-657,772,000
- FCF YoY
- 12.84%
- 52W High
- $25.32
- 52W Low
- $10.42
- 50D MA
- $18.06
- 200D MA
- $19.70
- Beta
- 0.20
- Avg Volume
- 3.19M
Get TickerSpark's AI analysis on SRPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 4, 26 | Boor Kathryn Jean | other | 16,875 |
| Jun 4, 26 | Mayo Stephen | other | 16,875 |
| Jun 4, 26 | Wigzell Hans Lennart Rudolf | other | 16,875 |
| Jun 4, 26 | BEHRENS M KATHLEEN | other | 16,875 |
| Jun 4, 26 | Connelly Deirdre P | other | 16,875 |
| Jun 4, 26 | Nicaise Claude | other | 16,875 |
| Jun 4, 26 | Chambers Michael Andrew | other | 16,875 |
| Jun 4, 26 | Barry Richard | other | 16,875 |
| Mar 11, 26 | Estepan Ian Michael | other | 1,097 |
| Mar 11, 26 | Wong Ryan Ho-Yan | other | 256 |
Our SRPT coverage
Recent articles, reports, and earnings notes.
No research on SRPT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SRPT report →Similar companies
Peers in the same neighborhood.